PR in the Philippines

TOKYO, Mar 3, 2026 - (JCN Newswire via SeaPRwire.com) - TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd. (Head office: Chuo-ku, Tokyo; Representative Director & CEO: Koichiro Tanaka), a company engaged in the industrial precious metals business of TANAKA, today announced a gold bump*1 transfer technology for the sintered gold (Au) bonding technology “AuRoFUSE™ Preforms.” This technology allows AuRoFUSE™ Preforms (gold bumps) to be formed even on semiconductor chips and substrates*2 with complex structures.Gold bump transfer substrate producedGold bumps after transferAdvantages of being able to transfer gold bumpsIn this technology, at first, gold bumps are formed on a substrate (transfer substrate). Then, the gold bumps are transferred to the target semiconductor chip or substrate. Openings are created on the silicon substrate used as the transfer substrate, and gold bumps are formed in them. By filling the entire opening, the gold bump is held by the substrate, eliminating the risk of dropping during the process. Meanwhile, during transfer, the gold bump shrinks under heat-treatment, forming a tiny gap between the opening and the gold bump. This allows easy extraction of gold bumps by the application of a force in the vertical direction.As the traditional gold bump formation process is a method that directly forms bumps on the target semiconductor chip or substrate, it is difficult to handle target chips and substrates with complex shapes, such as protrusions, dents, or open holes due to issues such as inconsistent resist heights.In this current transfer technology, gold bumps are manufactured separately and can be transferred only to the target locations. This allows the technology to also be applied to complex shapes. It can also be used with semiconductor chips and substrates that are difficult to process using photolithography*3 due to concerns about damage from stripping solutions and others.Manufacturing of transfer substrate and transfer and bonding process(1) Preparation of silicon substrate as transfer substrate(2) Application of photoresist to silicon substrate(3) Exposure and development of target pattern(4) Etching of silicon substrate to create holes(5) Application of AuRoFUSE™ using a squeegee, etc.(6) Vacuum drying of AuRoFUSE™ at room temperature and scraping off excess gold particles on the resist(7) Removal of resist to complete transfer substrate(8) Placement of transfer substrate on target (semiconductor chip or substrate) for gold bump formation, thermocompression at 10 MPa and 150℃ for one minute, followed by vertical lifting of substrate to transfer gold bumps(9) Bonding of post-transfer target through thermocompression at 20 MPa and 200℃ for 10 secondsAn illustration of the traditional gold bump formation process is available in the “Manufacturing of AuRoFUSE™ Preforms” section for reference on TANAKA’s website.About the sintered gold bonding technology “AuRoFUSE™ Preforms”Developed by TANAKA, “AuRoFUSE™ Preforms” is a bonding technology that forms bumps of all kinds of shapes using a paste comprising gold particles and an organic solvent. Through a thermocompression bonding process (20 MPa at 200℃ for 10 seconds), AuRoFUSE™ Preforms exhibits compression of approximately 10% in the compressive direction while showing minimal deformation in the horizontal direction. This gives them sufficient bonding strength*4 for practical applications. With the main component being gold, which has a high level of chemical stability, AuRoFUSE™ Preforms also provides excellent reliability after mounting.This technology enables miniaturization of semiconductor wiring and greater integration (higher density) for various types of chips. It is expected to contribute to the needs for miniaturization and better performance of semiconductors, which have been rising in recent years, including optical devices such as light-emitting diodes (LEDs) and semiconductor lasers (LDs), use in digital devices such as personal computers, smartphones, as well as in-vehicle components, micro-electromechanical systems (MEMS), and such.Traditionally, the main methods used in bump formation technology are soldering and plating. However, as solder tends to spread outward in molten state, there was the risk of short-circuiting through contact between electrodes as the bump pitch becomes finer. Meanwhile, plating can achieve a fine pitch, but because comparatively higher pressures are required during bonding, there is the possibility of causing chip damage. For reference, an illustration outlining the advantages of this technology compared with soldering and plating materials is provided in the “Comparison of AuRoFUSE™ Preforms with Other Materials” section on TANAKA’s website. This technology was developed to address these issues for use in next-generation high-density mounting and photonics-electronics integration devices.AuRoFUSE™ and TANAKA’s gold materialsAuRoFUSE™ is a paste-type bonding material containing a mixture of gold particles, with the particle diameter controlled to be submicron sized, and an organic solvent. Compared to the melting point of gold (approximately 1,064℃), bonding is possible at a low temperature of approximately 200℃.Gold is a material with low electrical resistance and extremely high thermal conductivity. Therefore, in power semiconductors that handle large currents and high-density chips that dissipate a lot of heat, it can efficiently dissipate heat and limit energy loss. Among precious metals, it is also particularly resistant to oxidation and has stable properties, making it less susceptible to corrosion after mounting and ion migration (a phenomenon in which metals move and cause short circuits). This allows it to maintain high reliability over long periods of time.TANAKA is highly skilled in precious metal material development technologies, developed since its establishment. It has used these technologies to undertake development of precious metal materials, such as gold, which plays a key role in the semiconductor field. With a system that integrates the entire chain of processes, from raw material procurement to material development, manufacturing, and recycling, TANAKA will contribute to the development of semiconductor technologies and the realization of a sustainable society while effectively using limited precious metal resources.*1 Bumps: Protruding electrodes*2 Substrate: Board that electrically and mechanically supports semiconductor chips mounted on it*3 Photolithography: Technology for forming fine circuit patterns on substrates*4 Bonding: Refers to shear strength (strength determined through application of a lateral load during testing)About TANAKASince its foundation in 1885, TANAKA has built a portfolio of products to support a diversified range of business uses focused on precious metals. TANAKA is a leader in Japan regarding the volume of precious metals it handles. Over many years, TANAKA has manufactured and sold precious metal products for industry and provided precious metals in such forms as jewelry and assets. As precious metals specialists, all Group companies in Japan and worldwide collaborate on manufacturing, sales, and technology development to offer a full range of products and services. With 5,591 employees, the group’s consolidated net sales for the fiscal year ended December 2024 were 846.9 billion yen.TANAKA Industrial Precious Metal Materials Portalhttps://tanaka-preciousmetals.comProduct inquiriesTANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.https://tanaka-preciousmetals.com/en/inquiries-on-industrial-products/Press inquiriesTANAKA PRECIOUS METAL GROUP Co., Ltd.https://tanaka-preciousmetals.com/en/inquiries-for-media/Press Release: https://www.acnnewswire.com/docs/files/20260303_EN.pdf  Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

ANTWERPEN, BELGIUM, Mar 3, 2026 - (ACN Newswire via SeaPRwire.com) - OMP, a leading provider of AI-powered supply chain planning solutions, launches Unison Decision-Centric Planning, a new approach that helps organizations move from reactive, process-driven planning to proactive, event-driven decision-making.Built on OMP's flagship Unison Planning™ platform, Unison Decision-Centric Planning combines advanced AI, autonomous agents, real-time scenario modeling, and human validation to accelerate decision velocity. The approach enables organizations to anticipate disruption, evaluate trade-offs, and act with confidence in increasingly volatile supply chain environments.From reactive to proactive supply chain planningTraditional planning cycles are often too slow to keep pace with today's volatility. Unison Decision-Centric Planning replaces static, process-driven planning with a dynamic, decision-first approach that continuously senses change, identifies relevant scenarios, and quantifies business impact. By aligning AI-driven intelligence with human judgment, organizations move from reactive firefighting to proactive value optimization."With Unison Decision-Centric Planning, we help customers move beyond reactive firefighting," said Tom Wouters, Chief Product Officer at OMP."By combining human expertise with advanced AI and scenario modeling, we enable confident, proactive decisions that drive agility, resilience, and measurable business impact."Human-AI synergy for smarter, faster decisionsUnison Decision-Centric Planning leverages UnisonIQ to orchestrate AI agents, generative AI assistants, and advanced optimization engines. Routine manual tasks are automated, freeing planners to focus on cross-functional collaboration and decision-making. Explainable AI ensures transparency and trust, while autonomous agents continuously monitor supply chain signals and act in real time.Proven impact at Evonik OxenoEvonik Oxeno, a leading producer of C4 chemicals, partnered with OMP to transition from reactive planning to always-on, scenario-based decision-making. By leveraging real-time insights and simulations through Unison Planning, planners can anticipate disruptions and respond faster, improving agility and overall business performance."Unison Decision-Centric Planning has reinforced trust in the system among planners and executives. Scenario-based decision-making enables us to respond faster and improve company performance," said David Kochanek, Supply Chain Solution Manager at Evonik Oxeno."Scenario-based decision-making enables us to respond faster and improve company performance."Always-on decision intelligence at scaleUnison Decision-Centric Planning introduces event-driven agents that continuously assess opportunities or risks, aligning decisions with strategic and financial objectives. By running hundreds of scenarios, organizations can anticipate disruption, optimize outcomes, and achieve measurable gains in service levels, cost efficiency, sustainability, and decision velocity."Organizations can run hundreds of scenarios to prepare for disruptions and optimize outcomes."Learn more about decision-centric planningDiscover how decision-centric planning can transform your supply chain. Explore OMP's resources, including the always-on e-book and the full Evonik Oxeno success story. Learn more.About OMPOMP helps companies facing complex planning challenges to excel, grow, and thrive by offering the best digitized supply chain planning solution on the market. Hundreds of customers in a wide range of industries - spanning consumer goods, life sciences, chemicals, metals, paper, packaging, plastics - benefit from using OMP's unique Unison Planning™.Solution and product inquiriesContact OMPMedia inquiriesKira Perdue (Carabiner)SOURCE: OMP Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, March 3, 2026 - (ACN Newswire via SeaPRwire.com) – MMG Limited (“MMG”, stock code: 1208)  has today announced its 2025 Annual Results, delivering record revenue and profit. The exceptional result reflects disciplined operational and financial management, supported by favourable commodity prices.Watch the Message from CEO:https://drive.google.com/file/d/17KFqXpd_2sjdZDKfBBMBv1ee09Zic-e6/view'usp=drive_linkSafety is MMG’s first value and the Company recorded a Total Recordable Injury Frequency (TRIF) of 2.06 per million hours worked for the full year 2025. The Significant Events with Energy Exchange Frequency (SEEEF) was 0.80 per million hours worked, up slightly from 0.78 per million hours worked in 2024.Total earnings reached record highs. EBITDA rose to US$3,412.1 million, while EBIT increased to US$1,999.1 million. MMG also generated record net operating cash flow of US$2,689.5 million and free cash flow of US$1,608.1 million. Net profit after tax increased to US$955.2 million (US$509.4 million attributable to equity holders), up from US$366.0 million (US$161.9 million attributable to equity holders) in 2024.“We ended the year strongly, delivering an excellent finish in terms of our operational and financial performance,” said MMG’s CEO Ivo Zhao. “This included Las Bambas achieving their second-highest annual copper production, up 27 per cent from 2024, with records set for annual ore mined, ore milled and overall recovery rates.”MMG’s balance sheet is now substantially stronger, with reduced net debt and a gearing ratio at a record low of 33 per cent. This included the Las Bambas joint venture (JV) dividend payment, which facilitated the early repayment of US$500 million in Khoemacau borrowings. The remaining funds were used to repay other debts, deleverage the company’s balance sheet and support the early stages of Khoemacau's expansion.MMG’s total copper production rose 27 per cent year-on-year to 506,899 tonnes, driven by technology, innovation and stable operation across both pits at Las Bambas. Las Bambas contributed US$4,447.0 million in revenue (49 per cent year-on-year growth), contributing the largest share of the Group’s revenue growth. Total zinc production increased by six per cent to 232,060 tonnes, underpinned by a record year at Dugald River. Precious metals production at Rosebery also performed well.“While we remain mindful of the dynamic market environment, we are focused on delivering our growth plans and harnessing emerging technologies to drive long-term value for shareholders,” said Mr Zhao. “An important contribution to MMG’s growth pipeline is our Khoemacau Expansion project. Our plan is to increase annual production capacity to 130,000 tonnes of copper in copper concentrate by 2028, with the potential for 200,000 tonnes over time.”During 2025, the Company’s market capitalization exceeded HK$100 billion, including strong demand for its first convertible bond.MMG’s 2025 Annual Results Report is available here.Las BambasKhoemacauDugald RiverRoseberyKinseverePhoto download link: https://drive.google.com/drive/folders/1o9ArIgbJSAT2z1UCt8ttB69L9l9jiebx'usp=drive_linkAbout MMGFounded in 2009, MMG’s vision is to create a leading international mining company for a low carbon future. The company is headquartered in Melbourne, Australia and Hong Kong and Beijing, China and listed on the Hong Kong Stock Exchange (HKEX1208).MMG’s portfolio supports copper, zinc and cobalt production, with soon to be nickel – products that are critical to achieving global decarbonisation and electrification targets. With operations in Australia, Botswana, the Democratic Republic of Congo and Latin America, the company makes a direct contribution to the economic and social development of its host countries.In 2025, MMG released its first nature strategy and progressed a refresh of its climate strategy. MMG's membership of the UN Global Compact further aligns the company with global leaders on human rights, climate action, and governance. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Kawasaki, Japan and Barcelona, Spain, March 3, 2026 - (JCN Newswire via SeaPRwire.com) - Fujitsu and BCN Port Innovation Foundation today announced a new agreement between Fujitsu Spain and the BCN Port Innovation Foundation to develop a proof of concept (PoC) for an ocean digital twin at the Port of Barcelona. This pioneering initiative is aimed at the regeneration of the marine environment, the protection of biodiversity and the promotion of the blue economy(1).Catalina Grimalt, CEO and President, BCN Port Foundation (left) and Ángeles Delgado, President of Fujitsu Technology Solutions S.A. (right) shaking hands after the signing ceremony to kick off the proof of concept.The project is based on the use of underwater drones combined with artificial intelligence and advanced analytics, capable of capturing high-resolution representations of the seabed. Using this non-destructive sensing approach, the digital twin will make it possible to visualize and quantify biodiversity, calculate biomass based on vegetation cover, and estimate blue carbon(2) associated with marine algae.This project lays the foundations for the BCN Port Innovation Foundation to have a unified digital platform that centralizes all information on port biodiversity and enables its long-term monitoring.With this initiative, Fujitsu reinforces its commitment to developing proprietary technology with social and environmental impact, aligned with climate neutrality goals and the protection of marine ecosystems, and consolidates its role as a technology partner in sustainable innovation projects in Spain.Fujitsu and the BCN Port Innovation Foundation plan to carry out the proof of concept in the Port of Barcelona during 2026.A new approach to measuring and protecting marine biodiversityGlobal marine ecosystems face a severe crisis due to global warming and ocean pollution. The EU is accelerating marine environmental conservation and restoration efforts, notably with the 2024 adoption of the Nature Restoration Law, which mandates marine ecosystem recovery.By integrating AI-enabled underwater data capture with advanced analytics, the Ocean Digital Twin transforms how marine ecosystems are measured, understood, and utilized. Autonomous surface and underwater vehicles follow optimized survey routes with real-time stabilization control, enabling consistent and repeatable seabed data acquisition and generating high-quality data suitable for AI processing.Machine learning models convert this data into quantitative environmental intelligence, estimating vegetation coverage, assessing habitat extent, and calculating blue carbon absorption. The technology also provides precise spatial data on seabed conditions, habitat distribution, and species types, creating a strong empirical foundation for the design and evaluation of conservation, restoration, and regeneration projects.In addition, the system enables continuous monitoring of multiple plant species, making it possible to analyze ecosystem evolution over time and anticipate potential impacts resulting from both climate change and port activity.Figure: Ocean Digital TwinEnvironmental simulation and data-driven decision-makingThe platform developed by Fujitsu enables the simulation of “what if” scenarios, helping pre-verification of environmental measures before they are implemented to prioritize investments based on their real impact. Thanks to the creation of a high-fidelity digital model, port authorities can identify priority areas for protection, as well as zones suitable for environmental restoration or rehabilitation.This simulation capability makes the digital twin a key tool for balancing port activity with the preservation of the natural environment, facilitating the design of more sustainable infrastructure and operations. Following a successful PoC, Fujitsu and BCN Port Innovation Foundation can collaborate to add regeneration and preservation simulation scenarios to the project.Blue economy, transparency and social engagementBeyond environmental conservation, the project could open up new opportunities within the blue economy, facilitating the potential development of marine research initiatives, environmental education and scientific outreach activities.Moreover, the visual and immersive nature of the digital twin enhances transparency and awareness, helping to bring knowledge of the marine environment closer to stakeholders and fostering greater understanding of the importance of protecting coastal ecosystems.Ángeles Delgado, president of Fujitsu Spain and Portugal, points out: “This project demonstrates how technology can become a true ally of sustainability. The ocean digital twin allows us to transform complex data from the marine environment into actionable information to protect biodiversity, promote blue carbon initiatives, and make evidence-based decisions.”(1) Blue economy:Achieving economic growth, job creation, and environmental preservation simultaneously while sustainably utilizing marine resources.(2) Blue carbon:Carbon captured by coastal and marine ecosystems through photosynthesis and subsequently stored in seabeds and deep seas.About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuAbout BCN Port InnovationBCN Port Innovation is a public-private collaboration initiative between the Port of Barcelona and the enterprise ecosystem aimed at promoting and validating innovative solutions in areas such as the logistics and port processes, mobility, and the energy transition, with a cross-cutting focus on digitalization and sustainability. More information: https://bcnportinnovation.org/en/Press ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiriesBCN Port InnovationMar Fernándeze-mail: m.fernandez@bcnportinnovation.org  Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

HONG KONG, March 3, 2026 - (ACN Newswire via SeaPRwire.com) – On 02 March 2026, Concord New Energy Group (“CNE Group”) signed a Memorandum of Understanding (MOU) in Singapore with Bridge Data Centres (BDC), a portfolio company of Bain Capital.Under the MOU, the parties will jointly explore diversified energy supply pathways integrating renewable energy and hydrogen solutions on a global basis to support the low-carbon transformation of data centre infrastructure. The collaboration includes the development of Singapore’s first barge-based hydrogen power generation solution designed specifically for artificial intelligence (AI) digital infrastructure.The partnership will encompass hydrogen power pathway studies, system integration design, energy storage deployment assessments, and optimization of power procurement mechanisms. Through these initiatives, both parties aim to enhance energy reliability, operational flexibility, and long-term sustainability for next-generation data centre campuses.CNE brings extensive expertise in renewable energy development and integrated energy systems, while BDC contributes leading operational capabilities in digital infrastructure. The collaboration is expected to accelerate the convergence of clean energy solutions and advanced computing infrastructure.As artificial intelligence and high-performance computing continue to reshape regional economies, this partnership will further support Singapore’s ambition to remain a leading digital hub powered by low-carbon energy.Bridge Data Centres (BDC)Headquartered in Singapore, Bridge Data Centres (BDC) is a leading hyperscale data centre platform in the Asia Pacific region backed by Bain Capital. The company focuses on the development and operation of high-performance digital infrastructure across multiple high-growth markets. BDC is committed to delivering resilient, reliable, and sustainable infrastructure solutions to support the rapid growth of cloud computing and artificial intelligence (AI) applications.Concord New Energy Group (CNE)Headquartered in Singapore, Concord New Energy Group is a renewable energy developer and operator listed on the Main Board of the Hong Kong Stock Exchange and the Singapore Exchange. With 20 years of experience in the renewable energy industry, CNE’s portfolio covers wind power, photovoltaic (PV) and energy storage projects. The Group has strong capabilities in project development, investment, construction and long-term asset management, and currently holds over 5GW of equity capacity globally. CNE remains committed to promoting the application of clean energy and providing integrated energy solutions to support sustainable development. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

- First glucokinase-activator (GKA) approval outside mainland China- Approval supports a differentiated approach to Type 2 diabetes (T2D) management- Hong Kong will serve as Hua Medicine’s launchpad for international market expansionSHANGHAI, HONG KONG, Mar 3, 2026 - (ACN Newswire via SeaPRwire.com) – Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552.HK) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (Trade name: MYHOMSIS(R)) has been approved for marketing by the Pharmaceutical Service of the Department of Health of the Hong Kong Special Administrative Region of China for the treatment of Type 2 diabetes in adults.Under Hong Kong's "1+" pharmaceutical regulatory innovation mechanism, the approval follows the acceptance of dorzagliatin’s New Drug Application (NDA) by the Hong Kong Department of Health in September 2025. As the first innovative drug for chronic metabolic diseases approved for marketing since the launch of "1+" mechanism, the successful rollout of dorzagliatin not only brings an entirely new treatment option for patients with Type 2 diabetes in Hong Kong, but also marks a crucial step in Hua Medicine's strategic layout to expand from China to the Southeast Asian and global markets with Hong Kong as its hub.Cao Beili, Vice President of Department of Corporate Operation and Great Bay Development of Hua Medicine, stated: “Among the three new drugs approved under the ‘1+’ mechanism, MYHOMSIS(R) is an innovative medicine developed in China that has obtained approval from the National Medical Products Administration (NMPA). It is also the first primary care drug product approved under the ‘1+’ mechanism.”Dr. Chen Li, Founder, Executive Director and CEO of Hua Medicine, stated: "The approval of dorzagliatin for marketing in Hong Kong is a significant milestone in the Company's development. As one of the first original innovative drugs to benefit from Hong Kong's '1+' mechanism, this achievement not only reflects Hong Kong's support for innovative drugs, but also validates the global competitiveness of China's independently developed innovative drugs. The launch in Hong Kong is a key step for Hua Medicine to enter the Southeast Asian and international markets. We will take Hong Kong as the hub to build a marketing network and R&D cooperation system radiating Southeast Asia and connecting the world, bringing China's independently developed innovative drugs to more diabetes patients in countries and regions around the globe. Meanwhile, we will continue to advance the marketing approval process of dorzagliatin in the Macao Special Administrative Region of China to achieve its full rollout in the Guangdong-Hong Kong-Macao Greater Bay Area, and relying on the regional advantages in mechanisms, talent and medical resources, we will advance the clinical expansion of new indications and the international promotion of MYHOMSIS(R)."Global First-in-Class & Local Clinical Data: Establishing a New Model for Restoring Glycemic Homeostasis in Diabetes TreatmentType 2 diabetes remains a progressive disease characterized by impaired glucose regulation and declining pancreatic β-cell function over time. While many therapies address downstream consequences of dysregulated blood glucose, dorzagliatin is a global first-in-class GKA innovative drug independently developed by Hua Medicine. Its core innovation lies in repairing the impaired function and expression of glucokinase (GK) in patients with Type 2 diabetes, thereby improving patients' glucose sensitivity from the source and ameliorating the imbalance of glycemic homeostasis. The drug acts on multiple key organs of glucose metabolism including the islets, intestines and liver, exerting a synergistic effect through multiple targets:- enhancing glucose-stimulated insulin secretion from pancreatic β-cells, - promoting GLP-1 release from intestinal L-cells, and - modulating hepatic glucose output through glycogen regulation.This coordinated, multi-organ profile differentiates dorzagliatin from existing oral antidiabetic therapies and reflects Hua Medicine’s focus on addressing glucose homeostasis dysregulation and controlling the progression of Type 2 diabetes and the occurrence of its complications from the source.Dorzagliatin was approved for marketing by the China National Medical Products Administration (NMPA) in September 2022 for two indications, both to improve blood glucose control for T2D patients:1) It can be used as mono-therapy treatment for drug-naïve T2D patients, as first-line treatment,2) When metformin hydrochloride alone exhibits poor blood glucose control in T2D patients, it can be used in combination with metformin hydrochloride.Since January 1, 2024, dorzagliatin is included in China’s National Reimbursement Drug List and has been prescribed to over 200,000+ patients in mainland China already. In June last year, the interim analysis of real-world research presented at the Scientific Sessions of the American Diabetes Association (ADA) further verified its efficacy and safety in a broad population.Leveraging Hong Kong's "1+" Mechanism to Accelerate Access to Innovative Drugs for Hong Kong ResidentsThe formulation and implementation of Hong Kong's "1+" pharmaceutical regulatory innovation mechanism is an important measure taken by the Hong Kong SAR Government to enhance the accessibility of medical innovation and attract high-quality global innovative drugs to launch in Hong Kong. This mechanism allows innovative drugs already approved in designated major markets (such as China, the United States, Europe, etc.) to secure marketing approval in Hong Kong through a simplified application pathway and data mutual recognition mechanism, which greatly shortens the time cycle from R&D to clinical access of innovative drugs for Hong Kong patients, while ensuring the safety and efficacy of the drugs.With its local clinical data, clear therapeutic value and good safety record in China, dorzagliatin has become one of the first original Chinese innovative drugs to be rapidly approved through Hong Kong's "1+" mechanism. This approval is an important practical achievement of the mechanism in enabling the launch of global innovative drugs in Hong Kong, which not only reflects the high recognition of the clinical value of dorzagliatin by the Department of Health of Hong Kong, but also highlights the core role of the "1+" mechanism in connecting the Chinese market and international pharmaceutical markets and accelerating the flow of innovative medical resources.Building on Hong Kong's Experience to Empower Global Diabetes ManagementDiabetes is a major challenge for global public health.  According to the 2025 Global Diabetes Map released by the International Diabetes Federation (IDF), the number of adults aged 20-79 with diabetes worldwide reached 589 million in 2024, and this figure is projected to rise to 853 million by 2050.  In Hong Kong, China, diabetes is also a prominent public health issue. According to the Population Health Survey 2020-2022 conducted by the Department of Health of Hong Kong, 6.9% of people aged 15 or above reported having been diagnosed with diabetes by a doctor, and an additional 1.8% had hyperglycemia without being diagnosed with diabetes. In 2022, more than 600 death registrations in Hong Kong were attributed to diabetes, ranking 11th among the leading causes of death.[1]Hong Kong has accumulated rich experience in diabetes management, forming a comprehensive system covering disease surveillance, prevention, screening, treatment and community management, and its community-based public-private partnership model for diabetes management has achieved remarkable results. Following its launch in Hong Kong, dorzagliatin is expected to be deeply integrated with the local mature diabetes management system, and help improve patients' quality of life, control disease progression and reduce medical burdens through personalized treatment plans.At present, Hua Medicine is collaborating with the research team led by Professor Juliana Chan, a world-renowned endocrinologist from the Chinese University of Hong Kong, to conduct the SENSITIZE series of studies to further explore the mechanism by which dorzagliatin improves pancreatic β-cell glucose sensitivity. The published results of the SENSITIZE 1/2 studies have shown that dorzagliatin can significantly improve the second-phase insulin secretion and β-cell glucose sensitivity in patients with glucokinase monogenic diabetes (GCK-MODY or MODY-2), and enhance basal insulin secretion in patients with newly diagnosed type 2 diabetes. In addition, dorzagliatin can also significantly improve the second-phase insulin secretion and β-cell glucose sensitivity in populations with impaired glucose tolerance (IGT).Hua Medicine will continue to deepen cooperation with top local research institutions and clinicians to further explore the potential of dorzagliatin in pre-diabetes intervention, early treatment and complication prevention, accumulate additional international clinical data, lay a solid foundation for the expansion of its indications and global market promotion, and establish personalized intervention and treatment management plans for patients with pre-diabetes and Type 2 diabetes.As a core hub of the Asian pharmaceutical market, Hong Kong, with its unique geographical location, advanced medical infrastructure, international business environment and close linkage with the Southeast Asian market, is expected to become the strategic starting point for Hua Medicine to expand into Southeast Asia and the global market. Relying on Hong Kong's advantage of pharmaceutical regulatory standards aligned with international norms and leveraging its financial and capital market strengths, Hua Medicine will further advance the registration and application of dorzagliatin in the Southeast Asian market to quickly cover the large population of diabetes patients in the region. Meanwhile, the Company will deepen cooperation with partners in the global pharmaceutical industry chain to accelerate the international commercialization of dorzagliatin.Forward-Looking StatementsThis document contains statements regarding Hua Medicine's and its products' future expectations, plans and prospects. Such forward-looking statements relate only to events or information as of the date on which the statements are made in this document and are subject to change in light of future developments. Except as required by law, the Company shall not be obligated to update or publicly revise any forward-looking statements or unforeseen events after the date of such statements, whether as a result of new information, future events or other circumstances. Please read this document carefully and understand that actual future performance or results of the Company may differ materially from expectations due to various risks, uncertainties or other statutory requirements.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment. In February 2026, dorzagliatin (Trade name: MYHOMSIS(R)) was approved for marketing by the Pharmaceutical Services of the Department of Health of the Government of the Hong Kong Special Administrative Region of China.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsEmail: ir@huamedicine.comMediaEmail:pr@huamedicine.com[1] https://www.chp.gov.hk/sc/features/37474.html Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

LOS ANGELES, CA, Mar 3, 2026 - (ACN Newswire via SeaPRwire.com) - Pacific Avenue Capital Partners ("Pacific Avenue"), a Los Angeles-headquartered private equity firm focused on corporate carve-outs and other complex transactions in the middle market, today announced that an affiliate of Pacific Avenue has entered into an agreement to acquire Care.com from IAC Inc. (NASDAQ:IAC).Care.com is a leading platform and brand in the growing $400 billion market for family care, anchored by the largest online network of background-checked child and senior caregivers in the U.S.Care.com operates both a scaled consumer marketplace and an enterprise benefits platform. Since 2007, more than 45 million people have turned to Care.com to find child care, senior care, pet care and housekeeping support. Care.com also partners with more than 700 employers, including many of the Fortune 100, to deliver care-related benefits that combine access to the Care.com platform and comprehensive backup care solutions provided in-home, in-center and through camps and activities, along with a broader suite of care support solutions.As a standalone company, Care.com will accelerate its enterprise expansion while continuing to strengthen its consumer marketplace. With Pacific Avenue's investment and support, the Company will move faster on product innovation, scale its employer partnerships, and enhance the platform experience for the millions of families and caregivers who rely on it."We are thrilled to announce the Care.com transaction, the first investment in Pacific Avenue Fund II. The transaction aligns perfectly with Pacific Avenue's track record of executing corporate carve-outs to acquire market-leading businesses. Care.com is an industry leader with a brand built on trust, a strong reputation, and a proven leadership team. Care.com has a clear path for growth as an independent, standalone company. We're excited to work with Brad, Michelle, and the Care.com team to unlock the company's full potential in serving families, caregivers, and its enterprise partners."- Chris Sznewajs, Founder and Managing Partner of Pacific Avenue"Caregiving is foundational to how families live and how businesses operate," said Brad Wilson, CEO of Care.com. "This partnership allows us to deepen our support for families and caregivers while expanding the ways we serve employers who recognize that caregiving is a workforce issue. We're entering this next chapter with strength, clarity, and a renewed commitment to building the most beloved platform for care.""Care.com enters this next chapter with a profitable foundation. This transaction positions us to further invest in our platform, expand our employer partnerships, and scale efficiently while maintaining the financial discipline that has strengthened our performance," said Michelle Arbov, Chief Financial Officer of Care.com.The transaction is subject to customary closing conditions and is expected to be completed in the first half of 2026.Moelis & Company LLC served as exclusive financial advisor to Pacific Avenue. Weil, Gotshal & Manges LLP served as legal advisor to Pacific Avenue.KPMG LLP provided accounting and tax advisory services. J.P. Morgan Securities LLC acted as exclusive financial advisor to IAC and Latham and Watkins LLP served as legal counsel to IAC.About Pacific Avenue Capital PartnersPacific Avenue Capital Partners is a global private equity firm headquartered in Los Angeles with an office in Paris. The firm is focused on corporate divestitures and other complex situations in the middle market. Pacific Avenue has extensive M&A and operations experience, allowing the firm to navigate complex transactions and unlock value through operational improvement, capital investment, and accelerated growth. Pacific Avenue takes a collaborative approach in partnering with strong management teams to drive lasting and strategic change while assisting businesses in reaching their full potential. Pacific Avenue has approximately $3.8 billion of Assets Under Management (AUM) as of September 30, 2025. For more information, please visit www.pacificavenuecapital.com.Contact InformationChris BaddonManaging Directorcbaddon@pacificavenuecapital.comSOURCE: Pacific Avenue Capital Partners Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com